56. Romieu I., Ferrari P., Rinaldi S. et al. Dietary glycemic index and glycemic load and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Am J Clin Nutr. 2012 Aug;96(2):345-55. doi: 10.3945/ajcn.111.026724. www. ncbi.nlm.nih.gov/pubmed/22760570 (дата обращения: 28.12.2020).
57. Thomas D., Elliott E.J. Low glycaemic index, or low glycaemic load, diets for diabetes mellitus. Cochrane Database Syst Rev. 2009 Jan 21;2009(1):CD006296. doi: 10.1002/14651858.CD006296.pub2. www.ncbi.nlm.nih.gov/pubmed/19160276 (дата обращения: 28.12.2020).
58. Thomas D., Elliott E.J, Baur L. Low glycaemic index or low glycaemic load diets for overweight and obesity. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005105. doi: 10.1002/14651858.CD005105.pub2. www.ncbi.nlm.nih.gov/pubmed/17636786 (дата обращения: 28.12.2020).
59. Connolly M.L., Tuohy K.M., Lovegrove J.A. Wholegrain oat-based cereals have prebiotic potential and low glycaemic index. Br J Nutr. 2012 Dec 28;108(12):2198-206. doi: 10.1017/S0007114512000281. www.ncbi.nlm.nih.gov/pubmed/22360862 (дата обращения: 28.12.2020).
60. Castro-Quezada I., Sanchez-Villegas A., Estruch R. et al. A high dietary glycemic index increases total mortality in a Mediterranean population at high cardiovascular risk. PLoS One. 2014 Sep 24;9(9):e107968. doi: 10.1371/journal.pone.0107968. www.ncbi. nlm.nih.gov/pubmed/25250626 (дата обращения: 28.12.2020).
61. Appleby P.N., Crowe F.L, Bradbury K.E. et al. Mortality in vegetarians and comparable nonvegetarians in the United Kingdom. The American Journal of Clinical Nutrition. 2016 Jan;103(1):218–230. https://doi.org/10.3945/ajcn.115.119461 https:// academic.oup.com/ajcn/article/103/1/218/4569305 (дата обращения: (дата обращения: 29.12.2020).
62. Poff A.M., Ari C., Seyfried T.N. et al. The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS One. 2013 Jun 5;8(6):e65522. doi: 10.1371/journal.pone.0065522. www.ncbi.nlm.nih.gov/ pubmed/23755243 (дата обращения: 28.12.2020).
63. Rieger J., B hr O., Maurer G.D. et al. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014 Jun;44(6):1843-52. doi: 10.3892/ ijo.2014.2382. Epub 2014 Apr 11. www.ncbi.nlm.nih.gov/pubmed/24728273 (дата обращения: 29.12.2020).
64. Gardner C.D., Trepanowski J.F., Del Gobbo L.C. et al. Effect of Low-Fat vs Low-Carbohydrate Diet on 12-Month Weight Loss in Overweight Adults and the Association With Genotype Pattern or Insulin Secretion. The DIETFITS Randomized Clinical Trial: JAMA. 2018 Feb 20;319(7):667–679. doi: 10.1001/jama.2018.0245. www.ncbi.nlm.nih. gov/pubmed/29466592 (дата обращения: 29.12.2020).
65. Howick J., Glasziou P., Aronson J.K. The evolution of evidence hierarchies: what can Bradford Hill’s ‘guidelines for causation’ contribute? J R Soc Med. 2009 May;102(5):186-94. doi: 10.1258/jrsm.2009.090020. www.ncbi.nlm.nih.gov/pubmed/19417051 (дата обращения: 29.12.2020).
66. ВОЗ. Вопросы и ответы о канцерогенности красного мяса и мясной продукции. Октябрь 2015 г. (Электронный ресурс) URJ: www.who.int/features/qa/cancer-red-meat/ru (дата обращения: 29.12.2020).
67. Pierozan P., Andersson M, Brandt I. et al. The environmental neurotoxin 0-N-methylamino-L-alanine inhibits melatonin synthesis in primary pinealocytes and a rat model. J Pineal Res. 2018 Aug;65(1):e12488. doi: 10.1111/jpi.12488. www.ncbi.nlm. nih.gov/pubmed/29528516 (дата обращения: 29.12.2020).
68. Engeset D., Braaten T., Teucher B. et al. Fish consumption and mortality in the European Prospective Investigation into Cancer and Nutrition cohort. Eur J Epidemiol. 2015 Jan;30(1):57–70. doi: 10.1007/s10654-014-9966-4. www.ncbi.nlm.nih.gov/ pubmed/25377533 (дата обращения: 29.12.2020).
69. Abdelhamid A.S., Brown T.J., Brainard J.S. et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2018 Jul 18;7(7):CD003177. doi: 10.1002/14651858.CD003177.pub3. www.ncbi. nlm.nih.gov/pubmed/30019766 (дата обращения: 29.12.2020).
70. Baye E., de Courten M.P., Walker K. et al. Effect of dietary advanced glycation end products on inflammation and cardiovascular risks in healthy overweight adults: a randomised crossover trial. Sci Rep. 2017 Jun 23;7(1):4123. doi: 10.1038/s41598-017-04214-6. www.ncbi.nlm.nih.gov/pubmed/28646140 (дата обращения: 29.12.2020).
71. Kim Y., Keogh J.B., Clifton P.M. Effects of Two Different Dietary Patterns on Inflammatory Markers, Advanced Glycation End Products and Lipids in Subjects without Type 2 Diabetes: A Randomised Crossover Study. Nutrients. 2017 Mar 29;9(4):336. doi: 10.3390/nu9040336. www.ncbi.nlm.nih.gov/pubmed/28353655 (дата обращения: 29.12.2020).
72. Lublin A., Isoda F., Patel H. et al. FDA-approved drugs that protect mammalian neurons from glucose toxicity slow aging dependent on cbp and protect against proteotoxicity. PLoS One. 2011;6(11):e27762. doi: 10.1371/journal.pone.0027762. www.ncbi.nlm.nih.gov/pubmed/22114686 (дата обращения: 29.12.2020).
73. Bridi J.C., Barros A.G., Sampaio L.R. et al. Lifespan Extension Induced by Caffeine in Caenorhabditis elegans is Partially Dependent on Adenosine Signaling. Front Aging Neurosci. 2015 Dec 8;7:220. doi: 10.3389/fnagi.2015.00220. www.ncbi.nlm.nih.gov/ pubmed/26696878 (дата обращения: 29.12.2020).
74. Poole R., Kennedy O.J., Roderick P. et al. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. BMJ. 2017 Nov 22;359:j5024. doi: 10.1136/bmj.j5024. www.ncbi.nlm.nih.gov/pubmed/29167102 (дата обращения: 29.12.2020).
75. Choi H.K., Curhan G. Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. Arthritis Rheum. 2007 Jun 15;57(5):816-21. doi: 10.1002/art.22762. www.ncbi.nlm.nih.gov/pubmed/17530681 (дата обращения: 29.12.2020).
76. Zhang Y., Yang T., Zeng C. et al. Is coffee consumption associated with a lower risk of hyperuricaemia or gout? A systematic review and meta-analysis. BMJ Open. 2016 Jul 8;6(7):e009809. doi: 10.1136/bmjopen-2015-009809. www.ncbi.nlm.nih.gov/ pubmed/27401353 (дата обращения: 29.12.2020).
77. Herraiz T., Chaparro C. Human monoamine oxidase enzyme inhibition by coffee and beta-carbolines norharman and harman isolated from coffee. Life Sci. 2006 Jan 18;78(8):795–802. doi: 10.1016/j.lfs.2005.05.074. www.ncbi.nlm.nih.gov/ pubmed/16139309 (дата обращения: 29.12.2020).
78. Van Gelder B.M., Buijsse B., Tijhuis M. et al. Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. Eur J Clin Nutr. 2007 Feb;61(2):226-32. doi: 10.1038/sj.ejcn.1602495. www.ncbi.nlm.nih.gov/ pubmed/16929246 (дата обращения: 29.12.2020).
79. Ding M., Bhupathiraju S.N., Chen M. et al. Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose-response metaanalysis. Diabetes Care. 2014 Feb;37(2):569-86. doi: 10.2337/dc13-1203. www.ncbi. nlm.nih.gov/pubmed/24459154 (дата обращения: 29.12.2020).
80. Wang L., Shen X., Y. et al. Coffee and caffeine consumption and depression: A meta-analysis of observational studies. Aust N Z J Psychiatry. 2016 Mar;50(3): 228-42. doi: 10.1177/0004867415603131. www.ncbi.nlm.nih.gov/pubmed/26339067 (дата обращения: 29.12.2020).
81. Lucas M., O’Reilly E.J., Pan A. et al. Coffee, caffeine, and risk of completed suicide: results from three prospective cohorts of American adults. World J Biol Psychiatry. 2014 Jul;15(5):377-86. doi: 10.3109/15622975.2013.795243. www.ncbi.nlm.nih.gov/ pubmed/23819683 (дата обращения: 29.12.2020).
82. Kennedy O.J., Roderick P., Buchanan R. et al. Systematic review with metaanalysis: coffee consumption and the risk of cirrhosis. Aliment Pharmacol Ther. 2016 Mar;43(5):562-74. doi: 10.1111/apt.13523. www.ncbi.nlm.nih.gov/pubmed/26806124 (дата обращения: 29.12.2020).
83. Malerba S., Turati F., Galeone C. et al. A meta-analysis of prospective studies of coffee consumption and mortality for all causes, cancers and cardiovascular diseases. Eur J Epidemiol. 2013 Jul;28(7):527-39. doi: 10.1007/s10654-013-9834-7. www.ncbi. nlm.nih.gov/pubmed/23934579 (дата обращения: 29.12.2020).
84. Cardin R., Piciocchi M., Martines D. et al. Effects of coffee consumption in chronic hepatitis C: a randomized controlled trial. Dig Liver Dis. 2013 Jun;45(6):499–504. doi: 10.1016/j.dld.2012.10.021. www.ncbi.nlm.nih.gov/pubmed/23238034 (дата обращения: 29.12.2020).
85. Wijarnpreecha K., Thongprayoon C., Thamcharoen N. et al. Association between coffee consumption and risk of renal cell carcinoma: a meta-analysis. Intern Med J. 2017 Dec;47(12):1422–1432. doi: 10.1111/imj.13621. www.ncbi.nlm.nih.gov/ pubmed/28892303 (дата обращения: 29.12.2020).
86. Lafranconi A., Micek A., De Paoli P. et al. Coffee Intake Decreases Risk of Postmenopausal Breast Cancer. A Dose-Response Meta-Analysis on Prospective Cohort Studies: Nutrients. 2018 Jan 23;10(2):112. doi: 10.3390/nu10020112. www. ncbi.nlm.nih.gov/pubmed/29360766 (дата обращения: 29.12.2020).
87. Guessous I., Dobrinas M., Kutalik Z. et al. Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension. Hum Mol Genet. 2012 Jul 15;21(14):3283-92. doi: 10.1093/hmg/dds137. www.ncbi.nlm.nih.gov/ pubmed/22492992 (дата обращения: 29.12.2020).
88. Cornelis M.C., El-Sohemy A., Kabagambe E.K., Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA. 2006 Mar 8;295(10):1135-41. doi: 10.1001/jama.295.10.1135. www.ncbi.nlm.nih.gov/pubmed/16522833 (дата обращения: 29.12.2020).
89. Palatini P., Benetti E., Mos L. et al. Association of coffee consumption and CYP1A2 polymorphism with risk of impaired fasting glucose in hypertensive patients. Eur J Epidemiol. 2015 Mar;30(3):209-17. doi: 10.1007/s10654-015-9990-z. www.ncbi. nlm.nih.gov/pubmed/25595320 (дата обращения: 29.12.2020).